IL-17–targeted agents are primarily used for the treatment of autoimmune and inflammatory diseases and have been associated with an increased risk of candidiasis, which is predicted given the association of chronic mucocutaneous candidiasis with mutations affecting the IL-17 pathway [47–49]. This evidence concerns the gene IL17A and Chronic mucocutaneous candidosis.